Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT study of MGN1703 maintenance therapy in advanced colorectal cancer
2009-017432-40Phase 2Completed
- Sponsor
- Mologen AG
- Start
- Dec 2009
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing MGN1703 maintenance with Placebo maintenance (2 arms). Primary endpoint: Median progression-free survival. Started Dec 2009; status: completed.
02
Drugs
lefitolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-017432-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017432-40.